PRTX Stock News Protalex Inc (PRTX) 7.7500 07/26/2014 20:56:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Protalex Inc (PRTX) 7.7500 $PRTX

Protalex Announces Data from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients Presented at the 2014 EULAR Annual European Congress of Rheumatology
Business Wire - Fri Jun 13, 5:30AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) was highlighted in a poster presentation at EULAR's Annual European Congress of Rheumatology being held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is now available on EULAR's website at www.eular.org and the complete poster is available on the Company's website at www.protalex.com.

Protalex Announces Preliminary Unblinded Findings from Cohorts 1-4 of U.S. Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Tue Jun 03, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced it has completed analysis of certain key parameters from its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA) (PRTX-100-104 Study). The primary endpoint of the study is to assess safety and tolerability, with secondary objectives to examine the effects of PRTX-100 on measures of disease activity, assessing the immunogenicity and evaluating the pharmacokinetic (PK) parameters after repeated doses, and determining possible relationships between the immunogenicity of PRTX-100 and safety, PK and efficacy parameters.

Protalex to Present Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients at the 2014 EULAR Annual European Congress of Rheumatology
Business Wire - Thu May 15, 7:02AM CDT
Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) will be highlighted in a poster presentation at EULAR's Annual European Congress of Rheumatology to be held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is available on EULAR's website and on the Company's website at www.protalex.com.

Protalex Announces Interim Findings from U.S. Phase 1(b) Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
Business Wire - Mon Feb 10, 1:00PM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced preliminary findings from a limited interim analysis of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study). PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The interim analysis included patients in the first four dosing cohorts of the five-cohort study through day 85 of the study protocol.

Protalex Announces Appointment of Marco M. Elser to Its Board of Directors
Business Wire - Wed Feb 05, 7:30AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that Marco M. Elser has been appointed to its Board of Directors. Mr. Elser is a partner with AdviCorp Plc, a London-based investment banking firm. Mr. Elser's appointment fills the vacancy on the Board resulting from the untimely passing of John Doherty last month. Mr. Doherty was a co-founder of Protalex and served as a director and a member of its Scientific Advisory Board since November 2009.

Protalex Announces Completion of $2.8 Million Private Placement
Business Wire - Thu Jan 23, 7:00AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that it has consummated a private placement financing to accredited investors of 471,334 shares of its common stock at $6.00 per share, yielding gross proceeds of $2,828,000. No commissions were payable in connection with the financing transaction. Proceeds of the financing will be used for working capital purposes, principally to fund ongoing clinical trials and studies and related activities. The investors in the offering were granted piggy-back registration rights in connection with certain registration statements filed by the company, subject to certain exceptions, including a registration statement filed in connection with a primary offering by the company.

Protalex to Present at the Rodman & Renshaw 15th Annual Healthcare Conference
Business Wire - Thu Sep 05, 7:00AM CDT
Protalex, Inc. (OTCBB RTX), a clinical-stage biopharmaceutical company, today announces its participation in the Rodman & Renshaw 15th Annual Healthcare Conference, to be held September 9-10, 2013 at the Millennium Broadway Hotel in New York City.

OTC Daily Alert Stock Watch - Protalex, Inc (OTCQB: PRTX)
WorldStockWire - Fri Aug 16, 3:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Protalex Announces PRTX-100 Phase I Data Published in The Journal of Clinical Pharmacology
Business Wire - Thu Aug 15, 12:57PM CDT
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced publication of the Company's Phase 1 study with PRTX-100 in healthy volunteers. This article entitled, "Safety, Pharmacokinetic, Immunogenicity, and Pharmacodynamic Responses in Healthy Volunteers Following a Single Intravenous Injection of Purified Staphylococcal Protein A," appears in the Journal of Clinical Pharmacology, Volume 53 (9).

Protalex Receives Third Interim Review from Independent Data Safety Monitoring Committee in its Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis
Business Wire - Tue Jul 23, 8:25AM CDT
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Independent Data Safety Monitoring Committee (SMC), the Company is continuing enrollment in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). PRTX-100 is a candidate drug incorporating a highly-purified form of Staphylococcal Protein A.

Protalex to Continue Phase 1b Trial of PRTX-100 in Patients with Active Rheumatoid Arthritis Following Data Safety Monitoring Committee Review
Business Wire - Thu Mar 07, 9:15AM CST
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its Data Safety Monitoring Committee, the Company is continuing enrollment and dosing of patients in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate and leflunomide in adults with active rheumatoid arthritis (RA). The dose of PRTX-100 for patients in the current treatment group (6.0 micrograms/kg) is four times that of the initial starting dosage (1.5 micrograms/kg).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 81

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 195

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 8

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 13

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 25

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 15

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 138

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Examining Consumer Trust: AI's Role in Holiday Shopping 2025

Updated Category News Views 206

Understanding Consumer Sentiments Towards AI in Holiday Shopping As the holiday shopping season approaches, a recent survey conducted by Sinch AB highlights a significant paradox affecting many brands this year. Although nearly half of consumers—about 48%—believe that artificial intelligence (AI) can streamline their shopping experience during peak times such as Black...

Continue Reading
Novonesis Concludes Successful Share Buyback with Strong Results

Updated Category News Views 201

Overview of Novonesis’ Share Buyback Program In the latest developments, Novonesis has successfully completed its share buyback initiative aimed at acquiring B shares, with a total commitment of up to EUR 100 million (approximately DKK 746 million) throughout 2025. This strategic move reflects the company's dedication to enhancing shareholder value and demonstrates its...

Continue Reading
Celebrating Women in Technology: Aragon Research Award Winners

Updated Category News Views 122

Celebrating Women in Technology Each year, Aragon Research proudly recognizes the groundbreaking achievements of women in the technology field. The 2025 Women in Tech Awards recognize individuals and innovations that not only advance their organizations but also inspire future generations of female leaders. This celebration serves to highlight the critical contributions...

Continue Reading
Caliber Introduces Innovative Opportunity Zone Fund Program

Updated Category News Views 86

Caliber (NASDAQ: CWD) launched its Qualified Opportunity Zone Fund Roll-Up program back in 2024, aiming to consolidate smaller funds into larger managed capital pools. This was a bold move for investors struggling with the complexities of Qualified Opportunity Funds (QOFs), and it certainly caught attention on the trading floor. Understanding QOFs: A Tax-Deferred...

Continue Reading
Intuitive Machines Achieves Record Q3 Growth and Contracts

Updated Category News Views 161

Intuitive Machines Celebrates Unprecedented Financial Growth Intuitive Machines, Inc. (NASDAQ: LUNR), a trailblazer in space exploration and services, proudly shares its impressive financial performance for the recent quarter. The company achieved remarkable revenue growth, securing notable contracts, and establishing a record cash balance. CEO Steve Altemus expressed his...

Continue Reading